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Abstract
Background: Preoperative chemotherapy (PCT) has become the standard of care in locally advanced
breast cancer. The identification of patient-specific tumor characteristics that can improve the ability to
predict response to therapy would help optimize treatment, improve treatment outcomes, and avoid
unnecessary exposure to potential toxicities. This study is to determine whether selected biomarkers
could predict pathologic response (PR) of breast tumors to three different PCT regimens, and to identify
a subset of patients who would benefit from a given type of treatment.
Methods: 118 patients with primary breast tumor were identified and three PCT regimens including DEC
(docetaxel+epirubicin+cyclophosphamide), VFC (vinorelbine/vincristine+5-
fluorouracil+cyclophosphamide) and EFC (epirubicin+5-fluorouracil+cyclophosphamide) were
investigated. Expression of steroid receptors, HER2, P-gp, MRP, GST-pi and Topo-II was evaluated by
immunohistochemical scoring on tumor tissues obtained before and after PCT. The PR of breast
carcinoma was graded according to Sataloff's classification. Chi square test, logistic regression and
Cochran-Mantel-Haenszel assay were performed to determine the association between biomarkers and
PR, as well as the effectiveness of each regimen on induction of PR.
Results: There was a clear-cut correlation between the expression of ER and decreased PR to PCT in all
three different regimens (p < 0.05). HER2 expression is significantly associated with increased PR in DEC
regimen (p < 0.05), but not predictive for PR in EFC and VFC groups. No significant correlation was found
between biomarkers PgR, Topo-II, P-gp, MRP or GST-pi and PR to any tested PCT regimen. After adjusted
by a stratification variable of ER or HER2, DEC regimen was more effective in inducing PR in comparison
with VFC and EFC regimens.
Conclusion: ER is an independent predictive factor for PR to PCT regimens including DEC, VFC and EFC
in primary breast tumors, while HER2 is only predictive for DEC regimen. Expression of PgR, Topo-II, P-
gp, MRP and GST-pi are not predictive for PR to any PCT regimens investigated. Results obtained in this
clinical study may be helpful for the selection of appropriate treatments for breast cancer patients.
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Background
Chemotherapy is used in both inoperable and operable
breast tumors, to promote tumor shrinkage and to render
these tumors treatable by radical mastectomy or radio-
therapy, or with the objective of down staging the tumor
so that breast-conserving surgery could become a viable
alternative to radical mastectomy. In recent years, preop-
erative chemotherapy has become the standard of care in
locally advanced breast cancers [1,2]. Previous clinical tri-
als have shown that preoperative chemotherapy allows
regression of the tumor in order to avoid mastectomy and
to treat clinically undetectable micrometastatic disease. In
addition, preoperative chemotherapy permits the assess-
ment of response of the primary tumor to a particular
chemotherapy regimen and provides an early opportunity
to alter the agents if the tumor appears clinically resistant.
Although several different classes of chemotherapeutic
drugs are applied in the preoperative setting include tax-
anes, anthracyclines and vinca alkaloids, etc., there are cur-
rently no standard regimens or protocols for preoperative
chemotherapy in breast cancer patients [2]. On the other
hand, a significant proportion of breast tumors are resist-
ant to chemotherapeutic agents. As a result, drug resist-
ance has become the major cause of cancer chemotherapy
failure and is largely responsible for breast cancer mortal-
ity. Therefore, the identification of patient-specific tumor
characteristics that can improve the ability to predict
response to therapy would help optimize treatment,
improve treatment outcomes, and avoid unnecessary
exposure to potential toxicities.
However, although the factors predicting response of
breast tumors to hormonal therapy are known [3-6], rela-
tively few studies to elucidate factors influencing the
response of patients to treatment of combination chemo-
therapy have been undertaken. Previous studies on the
response to chemotherapy in breast cancer either focused
on single chemotherapy regimen or single class of anti-
cancer drugs [7-9], or the combined treatment of chemo-
therapy and hormonal therapy [10,11], which may
provide limited information or blunt the effectiveness of
chemotherapy alone. Thus, more clinical studies investi-
gating the potential predictive or prognostic biomarkers
for breast cancer chemotherapy are needed.
Patients who exhibited pathologic complete response
(pCR) to chemotherapy showed better progression-free
survival and overall survival compared to those with resid-
ual tumor [12,13]. Therefore, pCR is now recognized as an
independent prognostic factor of patients with breast car-
cinoma. To assess whether the selected biomarkers may
play a role in predicting pathologic response of primary
breast tumors to preoperative chemotherapy, and to iden-
tify a subset of patients who would benefit from a given
type of preoperative treatment, 118 patients with operable
breast cancer treated with three different preoperative
chemotherapy regimens have been evaluated in the
present study. These patients with primary breast tumors
were subjected to three different chemotherapy regimens
before surgery, including DEC (docetaxel+epiru-
bicin+cyclophosphamide), VFC (vinorelbine/vincris-
tine+5-fluorouracil+cyclophosphamide) and EFC
(epirubicin+5-fluorouracil+cyclophosphamide). The
molecular makers measured in this study include estrogen
receptor (ER), progesterone receptor (PgR), human epi-
dermal growth factor receptor 2 (HER2), P-glycoprotein
(P-gp), multidrug resistance-related protein (MRP), glu-
tathione S-transferase pi (GST-pi) and topoisomerase-II
(Topo-II), based on their potential roles in modulating
tumor biology and sensitivity or resistance to anticancer
treatments [14-16].
Methods
Patient selection
One hundred and eighteen consecutive breast cancer
patients presented at the Zhejiang University Sir Run Run
Shaw Hospital, Hangzhou, China, who received preoper-
ative chemotherapy during the period of February 2002 to
January 2007 were enrolled in this study. Patients with
radiotherapy or endocrine therapy before surgery, and
those whose paraffin-embedded tissue from the biopsy
was insufficient to allow a pathologic diagnosis and eval-
uation of biomarkers, were excluded. The median age was
49 years (range, 30–84 years). Thirty-eight patients (32%)
were postmenopausal. The distribution of cases according
to tumor size, clinical node status, and menopausal status
Table 1: Patient characteristics (n = 118)
Characteristic Value
Age
Median 49
Range 30–84
Menopausal Status
Premenopausal 80 (68%)
Postmenopausal 38 (32%)
Histologic Type
Ductal Carcinoma 100 (84.7%)
Lobular Carcinoma 6 (5.1%)
Unclassified 12 (10.2%)
Clinical Primary Tumor
T1 19 (16.1%)
T2 19 (16.1%)
T3 74 (62.7%)
T4 6 (5.1%)
Chemotherapeutic Regimens*
DEC 58 (49.2%)
EFC 37 (31.4%)
VFC 23 (19.5%)
* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V 
vinorelbine or vincristineBMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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is shown in Table 1. This study was approved by the ethi-
cal committee of Sir Run Run Shaw Hospital. Informed
consents from patients were obtained for the use of paraf-
fin-embedded tumor tissue.
Treatment plan
Preoperative chemotherapy was started within 1 or 2 days
of diagnosis. Fifty-eight patients were treated with DEC
regimen containing 75 mg/m2 docetaxel i.v. on day 1, 60
mg/m2 epirubicin i.v. on day 1 and 500 mg/m2 cyclophos-
phamide  i.v. on day 1 every three weeks for 2 cycles.
Thirty-seven patients received EFC regimen containing
epirubicin 60 (or 70) mg/m2 i.v. on days 1 and 8, 5-fluor-
ouracil 500 mg/m2 i.v. on day 1 and cyclophosphamide
500 mg/m2 i.v. on day 1 every three weeks for 2 cycles.
Twenty-three patients were treated with VFC regimen con-
taining vinorelbine 25 mg/m2 i.v. or vincristine 1.3 mg/m2
i.v. on day 1, cyclophosphamide 375 mg/m2 i.v. on days
2, 4 and 6, and 5-fluorouracil 375 mg/m2 i.v. on days 1, 3
and 5 every three weeks for 2 cycles. Table 2 shows the
detailed employment of the above preoperative chemo-
therapy regimens in patients with primary breast tumors.
Breast cancer surgery was performed after 2 weeks of the
last cycle of chemotherapy.
Assessment of pathologic response
Tumor tissues were obtained 2–3 days prior to chemo-
therapy via core biopsy or during the surgery. Tumor sam-
ples obtained before and after chemotherapy were fixed
with 10% buffered-formalin, embedded in paraffin and
stained with hematoxylin and eosin. The pathologic
response of breast carcinomas was graded according to
Sataloff's classification (primary site response classifica-
tion) [17]. Given the nature of their results and using the
same guidelines, we re-named the four categories in Sata-
loff's classification into two groups: Group I as responders
(major pathologic response) and Group II as non-
responders (minor or no response), both of which con-
tain two subgroups. Therefore, patients were divided into
the following four groups: Group Ia, total or near total
therapeutic effect; Group Ib, subjectively more than 50%
therapeutic effect but less than total or near total; Group
IIa, less than 50% therapeutic effect, but effect evident;
and Group IIb, no therapeutic effect. Pathologic response
rate (pRR) was defined as a ratio of responders to total
number of tumors (responders plus non-responders).
Immunohistochemical assay
Immunohistochemical staining was completed in the
pathology laboratory of Sir Run Run Shaw Hospital. The
Table 2: Preoperative chemotherapy regimens employed in patients
Biomarker DEC (n = 58) EFC (n = 37) VFC (n = 23) All Patients (n = 118)
ER
negative 28 10 14 52
positive 30 27 9 66
positive rate(%) 51.7 73.0 39.1 55.9
PR
negative 31 19 12 62
positive 27 18 11 56
positive rate(%) 46.6 48.6 47.8 47.5
HER2
negative 24 16 9 49
positive 34 21 14 69
positive rate(%) 58.6 56.8 60.9 58.5
P-gp
negative 44 30 19 93
positive 14 7 4 25
positive rate(%) 24.1 18.9 17.4 21.2
MRP
negative 26 13 9 48
positive 32 24 14 70
positive rate(%) 55.2 64.9 60.9 59.3
GST-pi
negative 35 23 13 71
positive 23 14 10 47
positive rate(%) 39.7 37.8 43.5 39.8
Topo-II
negative 23 14 7 44
positive 35 23 16 74
positive rate(%) 60.3 62.2 69.6 62.7
* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V vinorelbine or vincristineBMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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sections cut at 4–6 μm were deparaffinized in xylene and
rehydrated in a series of graded ethanol. The slides were
immersed in 10 mM citrate buffer (pH 6.0) and boiled for
15 minutes in a pressure cooker with the lid on for antigen
retrieval. The slides were let cool down in the box at room
temperature for 20 min and then washed with phosphate
buffered saline (PBS). Endogenous peroxidase was
blocked with 0.3% H2O2 in methanol for 10 min, and
nonspecific binding was blocked by preincubation with
2% fetal calf serum in PBS with 0.1% sodium azide for 30
minutes [18].
The panel of markers detected by IHC was as followings:
ER (Neomarker, rabbit-mAb, clone sp1), PgR (Lab Vision,
rabbit-mAb, clone sp2), HER2 (Lab Vision, rabbit-mAb,
clone sp3), P-gp (ZSGB-Bio, mouse-mAb, clone c219),
MRP (GeneTech, mouse-mAb, clone 33A6), GST-pi
(Dako, rabbit-polyAb), Topo-II (Dako, mouse-mAb,
clone KI-S1). After washing three times in PBS, the slides
were incubated with the EnVision-HRP complex (Dako,
Carpinteria, CA) for 60 min. Finally, the slides were visu-
alized with diaminobenzidine (Dako) and counterstained
with hematoxylin. For substitute negative controls, the
primary antibody was replaced with PBS. Positive controls
included breast or colonic carcinomas known to exhibit
high levels of each marker.
Scoring of immunohistochemical assay
Immunohistochemical analysis reported in this study was
carried out in a single laboratory. All slides were reviewed
and scored independently by two pathologists without
knowledge of the demographic or treatment response
information. ER, PgR and Topo-II were scored as positive
when at least 10% of the carcinoma cell nuclei were
immunoreactive [7]. The intensity of membrane staining
of HER2 was evaluated according to the criteria set forth
by the DAKO Hercep Test: score 0 = no or up to 10%
membrane staining; score 1+ = partial and/or faint mem-
brane staining in more than 10% of tumor cells; score 2+
= weak to moderate complete membrane staining in more
than 10% of tumor cells; and score 3+ = strong complete
membrane staining in more than 10% of tumor cells [7].
Ascore of 0 and 1+ for HER2 was considered negative,
whereas 2+ and 3+were considered positive. We defined
ER negative, PR negative and HER2 negative as triple-neg-
ative phenotype, regardless of the expression of other
biomarkers [19]. Other combinations of ER, PgR and
HER2 expression was considered non-triple negative phe-
notype. The evaluation criteria for P-gp, MRP and GST-pi
expression were interpreted based on the percentage of
positive tumor cells: score 0 = no staining; score 1+ = up
to 25% staining; score 2+ = 25–50% staining; and score 3+
= more than 50% staining of tumor cells [20]. Ascore of 0
was considered negative, and all other scores were consid-
ered positive.
Statistical analysis
Descriptive studies were performed with SPSS 15.0 for
windows [10,11]. Chi square test (or Fisher's exact test)
and logistic regression were performed in univariate and
multivariate analysis, respectively, to determine the rela-
tionship between expression of biomarkers and patho-
logic response. Chi square test was also used for
association between different biomarkers. The relation-
ship between different chemotherapeutic regimen and
pathologic response was assessed with Cochran-Mantel-
Haenszel chi-square test adjusted for the effect of a strati-
fication variable ER. A p value of < 0.05 was considered
significant. Two-sided statistical tests were used in all the
above analyses.
Results
Response to preoperative chemotherapy
The pathologic responses were evaluated in all 118
patients at the end of two cycles of preoperative chemo-
therapy administration. According to the criteria defined
above, 26 of 118 (22.0%) patients had Ia (total/near total
therapeutic effect); 14 of 118 (11.9%) patients had Ib
(subjectively >50% therapeutic effect but <total/near total
therapeutic effect); 23 of 118 (19.5%) patients had IIa
(<50% therapeutic effect); and 55 of 118 (46.6%) patients
had IIb (no therapeutic effect). For further analysis,
patients treated with each combination chemotherapeutic
regimen were divided into two categories based on the
response to treatment: responders (Ia + Ib) and nonre-
sponders (IIa + IIb). There were 25 responders of 58
(43.1%) in DEC regimen group, 6 responders of 37
(16.2%) in EFC regimen, and 9 responders of 23 (39.1%)
in VFC regimen group.
Evaluation of immunostaining and the correlation among 
biomarkers
Expression of biomarkers was immunohistochemically
determined in biopsy specimens obtained before preoper-
ative chemotherapy. Positive ER, PgR and HER2 immu-
nostainings were noted in 55.9%, 47.5% and 58.5% of
the specimens, respectively. P-gp, MRP, GST-pi and Topo-
II positive staining were observed in 21.1%, 60.2%,
39.8% and 62.7% of tumors, respectively. Fifteen of all
118 specimens presented triple negative phenotype (neg-
ative ER, PgR and HER2). As shown in Table 3, statistically
significant correlations on expression of certain biomark-
ers were observed by using Chi square test. In brief, a
strong direct correlation was found between ER and PgR
receptor status. ER negative tumors were usually PgR neg-
ative, and only 6 tumors showed PgR positive in 52 ER
negative tumors. In contrast, ER expression was inversely
correlated with HER2, GST-pi and Topo-II. For example,
71.2% of ER negative tumors showed HER2 positive. In
addition, significantly direct correlation was also
observed between HER2 and Topo-II, as well as between
GST-pi and MRP (see Table 3).BMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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Correlation between expression of biological markers and 
pathologic response
Table 4 summarizes the results of univariate analyses for
the relationship between pathologic response and
biomarkers. Moreover, the multivariate analysis was
made by using the stepwise forward logistic regression
model for the co-variables including ER, PgR, HER2, P-gp,
MRP, GST-pi, Topo-II and three different chemotherapeu-
tic regimens. The statistically significant independent fac-
tor in multivariate analysis was listed in Table 5.
In univariate analysis and logistic regression analysis
(Tables 4 and 5), there was a clear-cut correlation between
the expression of ER and decreased pathologic response to
preoperative chemotherapy in all three different regimens
(p < 0.05). PgR was correlated with pathologic response to
DEC regimen but not other two regimens in univariate
analysis. However, no significant correlation between PgR
and any chemotherapy regimen was found in multivariate
analysis (p  > 0.05). HER2 expression was significantly
associated with increased pathologic response rate in
breast tumors treated with DEC regimen in both univari-
ate and multivariate analyses, suggesting that HER2 was
an independent predictive factor for DEC treatment (p =
0.026). However, no significant predictive effect of HER2
was found in EFC and VFC regimens, although HER2 neg-
ative tumors showed slightly higher pathologic response
rate than positive tumors (p > 0.05, see Table 4). Tumors
with triple negative phenotype (negative ER, PgR and
HER2) achieved significantly higher pathologic response
rate than non-triple negative phenotype (60.0% versus
30.1%, p = 0.022). Interestingly, in ER negative tumors,
the pathologic response rate of triple negative tumors was
similar with non-triple negative tumors (60.0% versus
62.2%, p = 0.885).
A correlation between Topo-II expression and greater
pathologic response to preoperative chemotherapy in
DEC regimen group was observed in univariate analysis (p
= 0.034) but not in multivariate analysis (p = 0.202). No
statistical significance between Topo-II expression and
pathologic response was achieved in EFC and VFC regi-
Table 3: Statistically significant correlations between 
biomarkers
Biomarkers Evaluated R Value p Value**
ER to PR 0.638 0.000
ER to HER2 -0.228 0.013
ER to GST-pi -0.254 0.005
ER to Topo-II -0.261 0.004
GST-pi to MRP 0.251 0.006
HER2 to Topo-II 0.204 0.027
**p < 0.05 is considered statistically significant
Table 4: Univariate analysis for pRR and biomarkers#
Biomarker DEC n = 58 EFC n = 37 VFC n = 23
pRR (%) p** pRR (%) p** pRR (%) p**
ER
negative 67.9 0.000** 50.0 0.003** 57.1 0.040**
positive 20.0 3.7 11.1
PR
negative 58.1 0.014** 26.3 0.180 58.3 0.089
positive 25.9 5.6 18.2
HER2
negative 16.7 0.001** 25.0 0.371 55.6 0.383
positive 61.8 16.2 28.6
P-gp
negative 38.6 0.223 13.3 0.315 42.1 1.000
positive 57.1 28.6 25.0
MRP
negative 32.0 0.137 7.7 0.394 22.2 0.228
positive 51.5 20.8 50.0
GST-pi
negative 42.9 0.963 8.7 0.173 30.8 0.417
positive 43.5 28.6 50.0
Topo-II
negative 26.1 0.034** 6.7 0.368 42.9 1.000
positive 54.3 22.7 37.5
# pRR: pathologic response rate
* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V vinorelbine or vincristine
**p < 0.05 is considered statistically significantBMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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mens (p = 0.368 and 1.000, respectively) in univariate
analysis. Moreover, no significant correlation was found
between biomarkers P-gp, MRP or GST-pi and pathologic
response to preoperative treatment of any chemotherapy
regimen investigated in this study.
Histological features of the primary breast tumors with 
different estrogen receptor status to preoperative 
chemotherapy
The histological effects of preoperative chemotherapy in
primary breast tumors with different ER status were eval-
uated by comparing biopsy and surgical samples taken
before and after chemotherapy. Tumor samples were fixed
in formalin for hematoxylin and eosin (H&E) staining
and immunohistochemical staining with anti-ERα anti-
body using standard protocols. Various pathological
changes were observed after preoperative chemotherapy,
which mainly included coagulative necrosis of tumor tis-
sue, fibrosis/hyalinization, as well as mixed inflammatory
infiltrate. Chemotherapy could also induce cytological
changes in tumor cells in cytoplasm and/or nuclear. For
example, the cytoplasm of tumor cells was either intensely
eosinophilic or clear with a vacuolated or foamy appear-
ance. Enlarged or bizarre nuclear with clumped chromatin
may be recognized. Furthermore, the volume of residual
tumor varied based on different chemotherapeutic effects.
In our study, most ER-negative breast tumors showed sig-
nificant better pathologic response to chemotherapy than
ER-positive tumors. As shown in Fig. 1, there were still
many survival tumor cells with ER positivity after the pre-
operative chemotherapy of EFC regimen in ER-positive
primary breast tumors. However, the ER-negative primary
tumor exhibited significantly improved pathologic
response to EFC treatment, which was demonstrated by
the dramatically reduced volume of residual tumor, as
well as the remarkable fibrosis and hyalinization of tissue
after the treatment.
Table 5: Multivariate analysis for pRR and biomarkers#
Treatment* Independent Factor OR p Value**
DEC (n = 58) ER 5.2 < 0.001
DEC (n = 58) HER2 0.2 0.026
EFC (n = 37) ER 26.0 0.007
VFC (n = 23) ER 10.7 0.047
All patients (n = 118) ER 11.6 < 0.001
# pRR: pathologic response rate
* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V 
vinorelbine or vincristine
**p < 0.05 is considered statistically significant
Immunohistochemical staining with ER (upper panel) and H&E staining (lower panel) Figure 1
Immunohistochemical staining with ER (upper panel) and H&E staining (lower panel). Stainings were performed 
on formalin-fixed, paraffin-embedded tissue sections of invasive ductal breast carcinoma, and photographed before and after 
preoperative chemotherapy treatment of EFC regimen, by using a Zeiss Axioskop40 Microscope and a Nikon E4500 camera. In 
ER+ tumor sample (left), tumor cells arranged in glands and clusters still showed active growth after the EFC chemotherapy 
treatment. Both core needle biopsy specimen and surgical specimen showed diffuse nuclear staining for estrogen receptor 
(diaminobenzidine chromogen). However, in ER- tumor sample (right), only a small nest of tumor cells remained survival after 
EFC treatment, with prominent stromal fibrosis and hyalinization. ER staining was negative in both biopsy and surgical speci-
mens. Data are representative of at least three separate experiments. Magnification:×100.BMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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Correlation between chemotherapy regimen and 
pathologic responses
As described above, our results indicate that ER is an inde-
pendent predictive factor for all three different chemo-
therapy regimens investigated in this study. Because the
positive rates of ER in tumors treated with DEC and VFC
regimens (51.7% in DEC group and 39.1% in VFC group)
were obviously lower than that in EFC group (73.0%),
Cochran-Mantel-Haenszel chi-square test was utilized to
compare the discrepancy of pathologic response to differ-
ent chemotherapy regimens, adjusted by the effect of the
stratification variable ER. After adjusted by the effect of
ER, our results indicate that breast tumors treated with
DEC regimen achieved higher pathologic response than
tumors treated with EFC or VFC regimen (DEC versus EFC,
p = 0.044; DEC versus VFC, p = 0.030), while the patho-
logic response rate induced by VFC regimen was similar to
that induced by EFC regimen (p = 0.495). The difference
on disparity of pathologic response rate between the
above two groups appears more remarkable in ER-positive
tumors than in ER-negative tumors. For example, only
one of total twenty six ER-positive tumors achieved major
pathologic response by treatment of EFC regimen (pRR =
3.7%), and in six of thirty ER-positive tumors in DEC
group achieved pathologic response (pRR = 20%),
although the difference did not reach statistical signifi-
cance (p = 0.105). While in ER-negative tumors, the differ-
ence on pathologic response between these two regimens
was relatively minor (67.9% in DEC regimen versus 50%
in EFC regimen, p = 0.449). Moreover, after adjusted by
the effect of stratification variable HER2, our data indi-
cated that tumors treated with DEC regimen achieved sig-
nificantly higher pathologic response than tumors treated
with other two regimens (DEC versus EFC, p = 0.004; DEC
versus VFC, p = 0.03) in HER2 positive tumors, while the
pathologic response rates induced by VFC or EFC regi-
mens were similar (p = 0.191). However, this superiority
of DEC regimen to other two regimens was not observed
in HER2 negative tumors.
Discussion
The future of cancer treatment lies in tailoring regimens to
individual patients by identifying response predictors and
developing novel agents. The preoperative chemotherapy
is an ideal clinical setting in which to validate the relation-
ship between tumor molecular profiling and treatment
outcomes, and to optimize therapies based on observed
effects on individual tumors. As a result, the evaluation of
pathologic response to preoperative chemotherapy pro-
vides an ideal platform to identify the potential predictive
factors of response to anticancer drugs. The present clini-
cal study was undertaken to determine whether the
expression of ER, PgR, HER2, P-gp, MRP, GST-pi and
Topo-II could affect the pathologic response of primary
breast tumors to three different preoperative chemother-
apy regimens including DEC, VFC and EFC. A clear defini-
tion of such factors would assist in the selection of
appropriate treatments for breast cancer patients.
Steroid hormone receptors, ER and PgR, are important
biological markers of breast carcinoma. Their status has
an established role in determining the tumor response to
hormonal therapy, but their role in predicting response to
chemotherapy is less clear [3-6,14]. Previous investiga-
tions evaluating the potential correlation between estro-
gen receptor status and pathologic response to
chemotherapy have produced contradictory data: ER-pos-
itive tumors respond either better [21], less well [22-27]
or the same [28-31], when compared with ER-negative
tumors. Some results can be confused by the use of
chemo-endocrine therapy, where the receptor-positive
population may have responded to the hormonal part of
the treatment [10,11]. The close correlation between ER
and PgR observed in this study may be explained by the
regulation of PgR expression by estrogen and estrogen
receptor [32,33]. However, although PgR was correlated
with pathologic response to DEC regimen in univariate
analysis (Table 4), no significant correlation between PgR
and any chemotherapy regimen was found in multivariate
analysis (Table 4 and 5). By using both univariate analysis
and logistic regression, our data indicate that ER is an
independent predictive factor of the pathologic response
to all three different chemotherapy regimens investigated
in this study including DEC, VFC and EFC. A clear corre-
lation between the expression of ER and decreased patho-
logic response to preoperative chemotherapy of all three
different regimens was observed in this study (Table 4 and
5, Fig. 1). In fact, through stable transfection of estrogen
receptor alpha into ER-negative human breast cancer cells,
we recently demonstrated that ER may mediate breast
tumor resistance to taxanes and vinca alkaloids through
inhibition of drug-induced apoptotic cell death [27]. Our
findings that ER-negative tumors exhibited improved
pathologic response to three different combination chem-
otherapy regimens suggest that ER may also mediate
breast cancer resistance to other chemotherapeutic drugs.
Our data provide strong support for the predictive value of
ER and indicate that ER seems to be more sensitive than
PgR in predicting pathologic response to preoperative
chemotherapy with DEC, VFC or EFC regimens.
Amplification and overexpression of certain oncogenes
have been associated with an aggressive natural history,
poor prognosis and altered sensitivity to chemotherapy
(either chemosensitization or chemoresistance). Among
them, one of the most promising new markers is the Her2
gene and its product (also designated c-erbB-2, c-neu)
[34]. HER2 encodes a 185-kDa transmembrane tyrosine
kinase active protein, which is a component of the epider-
mal growth factor receptor family [34]. HER2 is over-BMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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expressed in 25–30% of breast tumors. In current study,
the positive rate of HER2 was 58.5%, which was greater
than expected. It has been shown that more advanced
breast tumors usually have relatively higher expression
level of HER2 [35]. Thus, we think the high proportion of
HER2+ tumors may be related with the advanced clinical
stage of breast cancer patients enrolled in this study. There
is controversy about the overexperssion of HER2 in rela-
tion to response of breast tumor cells to chemotherapy
[36-39], and the underlying mechanism involved in these
processes have not been clearly elucidated. In the present
study, both univariate and multivariate analysis indicated
that high level of HER2 expression was significantly asso-
ciated with increased pathologic response rate in breast
tumors treated with DEC regimen, suggesting that HER2
might be an independent predictive factor for DEC treat-
ment (Table 4). However, no significant predictive effect
of HER2 was found in patients treated with EFC or VFC
regimens (p > 0.05, see Table 4). Triple-negative breast
cancer is a recent term and refers to cancers that do not
express ER, PgR and HER2 receptors. Histologically, such
cancers are poorly differentiated, and most fall into the
basal subgroup of breast cancers, characterized by staining
for basal marker (i.e. cytokeratin) [19]. Clinically, triple-
negative cancers were characterized by an aggressive clini-
cal history, and some reports indicate that this group of
breast cancer patients was associated with poor clinical
outcome [19]. Very few studies have investigated the path-
ologic response of triple-negative breast cancers to chem-
otherapy [40-42]. In the present study, we found that
breast tumors with triple-negative phenotype achieved
significantly higher pathologic response rate than nontri-
ple-negative phenotype (60.0% versus 30.1%, p = 0.022).
Interestingly, in ER-negative tumors, the pathologic
response rate of triple-negative tumors was similar with
nontriple-negative tumors (60.0% versus  62.2%,  p  =
0.885), suggesting that ER might be a more important
biomarker in predicting pathologic response of breast
tumors to preoperative chemotherapy than PgR and
HER2.
P-gp and MRP, two ATP-dependent drug transport
pumps, have been indicated to confer resistance to a
number of chemotherapeutic agents such as paclitaxel,
epirubicin and vinblastine [16]. The expression levels of
these two transporters are 21.1% and 60.2%, respectively,
in our tumor samples. A significant correlation between
expression of MRP and GST-pi was observed in this study
(Table 3), which is consistent with previous reports indi-
cating that GSH is necessary for MRP-mediated cellular
efflux of certain drugs and detoxification of anticancer
agents involves a combined action of GSTs and MRPs
[43,44]. A significant positive correlation between P-gp
expression and a poor clinical response to chemotherapy
was reported in some studies [45,46]. However, no statis-
tical association between the expression of P-gp, com-
bined MRP and GST-pi with pathologic response to any of
the three preoperative chemotherapy regimens was
observed in the present study and several other reports
[43,44,47]. On the other hand, Topo-II is an important
DNA binding enzyme that modifies DNA topology. Topo-
II gene is located at chromosome band 17q12-21, close to
the Her2 gene [15]. A significant proportion of breast can-
cers with Her2 amplification show simultaneous amplifi-
cation of Topo-II [24], which coincides with the
significant correlation between Topo-II and HER2 protein
expression observed in this study (Table 3). Some clinical
investigations have shown certain association between
Topo-II and response of breast cancer to chemotherapy
[48-50], but some others failed to confirm this association
[51]. In our study, a statistical significance between Topo-
II expression and pathologic response to preoperative
chemotherapy was only observed in DEC regimen in uni-
variate analysis (p = 0.034), but this significance was not
confirmed in multivariate analysis (p = 0.202).
By using a modified method of Sataloff DM to classify the
pathologic response, 40 of total 118 patients in this study
were classified as responders (pRR = 22.9%). Further, we
evaluated the pathologic response induced by each chem-
otherapeutic regimen with Cochran-Mantel-Haenszel chi-
square test adjusted by ER or HER2, two independent pre-
dictive biomarkers observed in this study. Our data show
that after adjusted by the effect of ER, the pathologic
response rate induced by DEC regimen was significantly
higher than EFC and VFC regimens, while the later two
regimens did not reach statistical significance. The above
difference was particularly remarkable in ER-positive
breast tumors than ER-negative tumors. After adjusted by
the variable HER2, DEC regimen was also most effective
in inducing pathologic response in HER2 positive breast
tumors. These data may suggest a potential advantage in
inducing relatively high pathologic response in primary
breast tumors by DEC regimen compared with EFC and
VFC regimens.
Conclusion
Our data show that ER is an independent predictive factor
of pathologic response to three different preoperative
chemotherapy regimens including DEC, EFC and VFC in
breast tumors. ER-negative tumors exhibited significantly
increased benefit from the above preoperative regimens
compared to ER-positive tumors. HER2 is an independent
predictive factor in tumors treated with DEC regimen, but
not in tumors exposed to EFC or VFC regimens. Expres-
sion of PgR, Topo-II, P-gp, MRP and GST-pi were not pre-
dictive for pathologic response to any of the three
preoperative chemotherapy regimens. Results obtained in
this clinical study may provide valuable information on
the potential correlation between selected biomarkersBMC Cancer 2009, 9:226 http://www.biomedcentral.com/1471-2407/9/226
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with pathologic response to preoperative chemotherapy
in breast tumors, which may be helpful in the selection of
appropriate treatments for breast cancer patients.
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